Xilio Therapeutics (XLO) Change in Account Payables (2020 - 2026)

Xilio Therapeutics has disclosed Change in Account Payables across 7 years of filings, most recently posting -$1.7 million for Q1 2026.

• Change in Account Payables for Q1 2026 came in at -$1.7 million, down 184.75% year-over-year; the trailing twelve-month figure through Mar 2026 was -$938000.0 (down 175.58% YoY), and the FY2025 annual result was $152000.0, down 90.04% from the prior year.
• Change in Account Payables came in at -$1.7 million for Q1 2026 at Xilio Therapeutics, down from $428000.0 in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $2.1 million in Q2 2025 to a low of -$1.8 million in Q3 2025.
• The 5-year median for Change in Account Payables is -$305000.0 (2024), against an average of -$92941.2.
• Across the five-year window, Change in Account Payables jumped 465.75% in 2024 and tumbled 542.14% in 2025, its largest moves.
• Xilio Therapeutics' Change in Account Payables stood at $1.5 million in 2022, then plunged by 130.06% to -$438000.0 in 2023, then surged by 465.75% to $1.6 million in 2024, then plunged by 73.28% to $428000.0 in 2025, then plunged by 492.52% to -$1.7 million in 2026.
• The last three Change in Account Payables figures came in at -$1.7 million (Q1 2026), $428000.0 (Q4 2025), and -$1.8 million (Q3 2025), per Business Quant data.